I-MED Surgical, a division of I-MED Pharma, announced today that Health Canada has granted approval of the Rayner C-flex® and Superflex® aspheric intraocular lenses for visual correction following cataract surgery. As the exclusive Canadian distributor, I-MED Surgical will begin a phased commercial launch of these new lenses with full distribution expected by Q4 2010.
Online PR News – 09-July-2010 – – I-MED Surgical, a division of I-MED Pharma, announced today that Health Canada has granted approval of the Rayner C-flex® and Superflex® aspheric intraocular lenses for visual correction following cataract surgery. As the exclusive Canadian distributor, I-MED Surgical will begin a phased commercial launch of these new lenses with full distribution expected by Q4 2010.
Rayner C-flex Aspheric and Superflex® Aspheric IOLs are spherically aberration-neutral with the aspheric modification being applied to the anterior surface of the IOL, providing uniform refractive power from the centre of the optic to its edge, for optimal visual outcomes. The depth of field of this lens is very similar to standard IOLs whilst having the advantages discussed above. In addition, the Rayner C-flex Aspheric and Superflex® Aspheric IOLs offer the technology of the existing IOL platform. These include the Amon-Apple Enhanced Square Edge for exemplary low posterior capsular opacification rates, AVH (anti-vaulting haptic) Technology for optimal centration, and a single use Soft-tipped injector capable of IOL insertion through a sub 3mm incision.
The Rayner C-flex (970C) Aspheric and Superflex® (920H) Aspheric
• Increased contrast sensitivity
• Increased functional visual acuity
• Optimised visual outcomes even under reduced lighting conditions
• Increased depth of field compared with designs corrected for corneal spherical aberration, such as negative aberration designs
• Less susceptible to the effects of tilt and decentration compared with negative aberration designs – a benefit which is further enhanced by the incorporation of AVH Technology®.
“The addition of the Rayner aberration-neutral optic technology intraocular lens (IOL) selection to our offering allows I-MED Surgical to provide our clients a complete and totally innovative IOL line which permits the surgeon to offer their patients the most modern and effective corrective implantable lenses following cataract surgery,” said Dr. Ilan Hofmann, President, I-MED Pharma. “The design, IOL material, optics and delivery system is unmatched in quality and performance by any other supplier currently on the market. I-MED Surgical, a company with more than two decades of experience in the ophthalmic surgical market, is pleased to offer Canadian ophthalmologists the best selection of intraocular lenses manufactured by Rayner, the company that invented intraocular lenses.”
I-MED Pharma innovates and distributes medical, surgical and veterinary eye care products. I-MED remains uniquely focused on ophthalmology and is divided into three functional business units: Animal Health, Pharma and Surgical. It researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal transplants, dry eye, and glaucoma.
For more information please visit www.imedpharma.com